Sol Gel Technologies Ltd Total Liabilities
Sol Gel Technologies Ltd total liabilities. Based on the latest financial reports, Sol Gel Technologies Ltd (SLGL) has total liabilities worth $5.66 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SLGL asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Sol Gel Technologies Ltd (2014–2025)
Total liabilities of Sol Gel Technologies Ltd from 2014 to 2025. This chart illustrates how Sol Gel Technologies Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Sol Gel Technologies Ltd (SLGL) long-term investment share to see how much of total assets are deployed in long-term investments.
Sol Gel Technologies Ltd Competitors by Total Liabilities
The table below lists competitors of Sol Gel Technologies Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aprogen Healthcare & Games Inc
KQ:109960
|
Korea | ₩15.37 Billion |
|
OP Bancorp
NASDAQ:OPBK
|
USA | $2.42 Billion |
|
Izmir Demir Celik Sanayi AS
IS:IZMDC
|
Turkey | TL33.50 Billion |
|
Xsolla SPAC 1 Class A Ordinary Shares
NASDAQ:XSLL
|
USA | $405.10K |
|
Translational Development Acquisition Corp. Ordinary Shares
NASDAQ:TDAC
|
USA | $7.79 Million |
|
Alta Equipment Group Inc
NYSE:ALTG
|
USA | $1.36 Billion |
|
RideNow Group, Inc.
NASDAQ:RDNW
|
USA | $391.10 Million |
|
Nanexa AB
ST:NANEXA
|
Sweden | Skr21.81 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Sol Gel Technologies Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Sol Gel Technologies Ltd assets under control.
Liquidity & Leverage Metrics
Sol Gel Technologies Ltd Total Liabilities Ratios Explained
Sol Gel Technologies Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sol Gel Technologies Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sol Gel Technologies Ltd (2014–2025)
The table below shows the annual total liabilities of Sol Gel Technologies Ltd from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.11 Million | +1.57% |
| 2024-12-31 | $7.00 Million | +5.31% |
| 2023-12-31 | $6.64 Million | +50.46% |
| 2022-12-31 | $4.42 Million | -67.52% |
| 2021-12-31 | $13.60 Million | +63.56% |
| 2020-12-31 | $8.31 Million | -5.93% |
| 2019-12-31 | $8.84 Million | +53.06% |
| 2018-12-31 | $5.77 Million | -91.51% |
| 2017-12-31 | $68.01 Million | +60.71% |
| 2016-12-31 | $42.32 Million | +114.16% |
| 2015-12-31 | $19.76 Million | +323.99% |
| 2014-12-31 | $4.66 Million | -- |
About Sol Gel Technologies Ltd
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treat… Read more